ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
Kevin James Craig sold 11,563 shares of ATAI on 21 March at $1.35 per share, worth a total of $16K. They now own 8,437 ATAI shares, or a 58% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
